Every 10-Q that Clearwater Analytics Hldgs Inc (CWAN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CWAN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CWAN filings page.
Clearwater Analytics Holdings, Inc. reports strong top-line growth but a small loss for the quarter ended March 31, 2026, while progressing toward a go‑private merger. Revenue rose to $221.2 million from $126.9 million a year earlier, driven by organic growth and the 2025 Enfusion and Beacon acquisitions.
Despite higher scale, Clearwater posted a net loss attributable to the company of $2.8 million, compared with net income of $6.5 million, mainly due to increased interest expense of $12.6 million and sharply higher amortization of acquired intangibles. Adjusted EBITDA grew to $77.4 million, maintaining a 35% margin, reflecting underlying profitability after adding back non‑cash and transaction costs.
The balance sheet shows total assets of $3.03 billion, including $1.27 billion of goodwill and $660.7 million of intangibles from recent deals, and notes payable of $806.4 million under the 2025 Credit Agreement. Annualized recurring revenue reached $871.8 million, with a net revenue retention rate of 108%, underscoring sticky, expanding client relationships.
Clearwater also highlights its pending acquisition by an investor group led by Permira and Warburg Pincus in a transaction valued at approximately $8.4 billion. Each share of Class A common stock is expected to be converted into $24.55 in cash upon closing, subject to remaining conditions including Australian FIRB approval. Following completion, the stock will be delisted from the NYSE.
Clearwater Analytics (CWAN) reported Q3 2025 results. Revenue rose to $205.1M from $115.8M a year ago as recent acquisitions contributed, with gross profit of $134.5M and operating income of $6.6M. Higher interest and amortization drove a net loss of $10.5M. Year-to-date revenue reached $513.9M.
The company completed the acquisitions of Enfusion and Beacon, recording goodwill of $1.27B and intangible assets of $714.1M at quarter end. Operating cash flow was $120.6M for the nine months, while investing cash outflows of $988.5M reflected deal activity. CWAN entered a 2025 Credit Agreement with $800M term loans and a $200M revolver; the net carrying amount of notes payable was $838.9M. Cash and equivalents were $60.8M. As of November 3, 2025, shares outstanding were 288,154,032 Class A and 4,506,422 Class B; Class C and D were converted and retired on June 12, 2025.